FRAMINGHAM, MA, July 7, 2008—GTC Biotherapeutics, Inc. (“GTC”, Nasdaq: GTCB) announced today that Geoffrey Cox, Ph.D., GTC’s Chairman and CEO, is scheduled to present on Wednesday, July 9, 2008 at 3:30 p.m. during the Collins Stewart Fourth Annual Growth Conference. The conference is being held at the Mandarin Oriental Hotel in New York, New York from July 8-10, 2008.
The presentation will be webcast live and can be accessed by logging onto www.gtc-bio.com. The replay can be accessed from this same website and will be available within 24 hours of the presentation.
About GTC BiotherapeuticsGTC Biotherapeutics develops, supplies, and commercializes therapeutic proteins produced through transgenic animal technology. ATryn®, GTC’s recombina
nt human antithrombin, has been approved for use in Europe and has begun the review process in the United States under a rolling Biologics License Application. In addition to ATryn®, GTC is developing a portfolio of recombinant human plasma proteins with known therapeutic properties. These proteins include recombinant forms of human coagulation factors VIIa, VIII, and IX, which are used for the treatment of hemophilia, and alpha-1 antitrypsin. GTC also has a monoclonal antibody portfolio that includes a monoclonal antibody to CD20 and a monoclonal antibody to CD137. GTC’s intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC’s transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as proteins that are required in large volumes. Additional information is available on the GTC web site, http://www.gtc-bio.com. CONTACT:GTC Biotherapeutics, Inc.
Thomas E. Newberry
Vice President, Corporate Communications and Government Relations
(508) 370-5374 or tom.newberry@gtc-bio.com
Copyright 2008 GTC Biotherapeutics, All Rights Reserved